Assessment of SMS and Smartphone Interventions for OneTouch Reveal® Experiences

Diabetes Mellitus Clinical Trial

Official title:

Assessment of SMS and Smartphone Interventions for OneTouch Reveal® Experiences

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02429024
• Other study ID #: 3132245
• Status: Completed
• Phase: Phase 4
• First received: April 14, 2015
• Last updated: September 12, 2016
• Start date: May 2015
• Est. completion date: April 2016

Study information

• Verified date: September 2016
• Source: LifeScan
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

Assessment of SMS and Smartphone Interventions for OneTouch Reveal® Experiences with patients with Type I and Type II diabetes.

Description:

The primary objective is to demonstrate improved A1c in study subjects with type 1 and type 2 diabetes using the OneTouch Verio® Flex BGM and the OneTouch Reveal® Mobile APP system over a period of 24 weeks, compared to subjects using the OneTouch Verio® Flex BGM.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 138
• Est. completion date: April 2016
• Est. primary completion date: April 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Male or female, at least 18 years old (or the legal age of consent in the jurisdiction in which the study is taking place) to 70 years old, inclusive;

• Has an A1c =7.5 and = 11.0% at screening visit;

• It is medically appropriate in the opinion of the investigator for the Subject to attempt to achieve a level of glycemic control in line with the ADA guidelines on glyceamic recommendations (<7.0% A1c, pre-prandial capillary glucose of 3.9-7.2mmol/l and peak post-prandial glucose of <10.0mmol/l);

• Diagnosed with T2DM or T1DM for = 3 month prior to screening;

• Currently performing SMBG at home for diabetes management decisions and willing to test SMBG = 1 per day if subject has Type 2 diabetes and is on AHA and/or non-insulin injectable (e.g. GLP-1) only, = 2 per day if on basal insulin or premixed insulin; and test = 3 times per day if subject has Type 2 diabetes and is on MDI or subject has Type 1 diabetes.

• Willing to send and receive SMS messages using a sponsor smartphone at 2 weekly intervals throughout the study (note: this inclusion applies to all subjects regardless of whether they are subsequently randomized to control or intervention)

• Is located in an area that can send and receive SMS messages and has access to a phone signal to use the 3G network as required

• On a stable dose of anti-hyperglycemic agents (AHA), including oral hypoglycemics (OAs), non-insulin injectables (e.g. GLP-1) or insulin therapy = 2 months prior to screening; (Note: the definition of stable includes subjects who routinely self-adjust insulin based on 'in the moment' SMBG values. Stable does not include actual diabetes therapy changes (e.g. new oral medications, initiating insulin or changing insulin regimen, insulin to carb ratio changes or basal to bolus insulin progression)

• Anti-hyperglycemic agents (AHA)(OAs or GLP-1s) must be consistent with UK labeling for the subject's insulin type;

• Willingness to not use a CGM device during the study period;

• Willingness to notify the study staff if they become pregnant during the study;

• Willingness to practice an appropriate form of birth control during the study if of child bearing potential;

• Able to communicate (speak, read and write) in English, and able to understand and sign the required study documents;

• Have signed an informed consent (or regional equivalent) document indicating they understand the purpose and procedures of the study;

Exclusion Criteria:

• Is unlikely to be compliant with the currently prescribed diabetes regimen, in the opinion of the study staff;

• Currently pregnant or planning pregnancy within the duration of the study or breast feeding;

• Has unstable (rapidly progressing) retinopathy that in the opinion of the study staff may require surgical treatment (including laser photocoagulation) during the study

• Is currently on or received treatment during the past 3 months with Systemic corticosteroids or anti-psychotic drugs or prescription cannabinoid

• Is currently psychiatrically unstable in the opinion of the study staff

• Has known clinically significant and/or unstable medical conditions, in the opinion of the study staff, including: Cardiovascular disease, Hematological disease, Hepatic disease, Gastrointestinal disease, Endocrine/metabolic disorders and Neurologic disease

• Malignant neoplasm requiring treatment in the past 5 years, other than basal cell/squamous cell carcinoma of the skin

• History of major surgery within 6 months

• Has had any condition that in the opinion of the study staff that would complicate or compromise the study, or the well being of the Subject

• Subject is an employee of the investigator or clinical site;

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Diabetes Mellitus

Intervention

Device:
• OneTouch Reveal® Mobile APP
Diabetes management application for use on a mobile phone.
• OneTouch Verio® Flex BGMS
Blood Glucose Monitoring System (BGMS)

Locations

Country	Name	City	State
United Kingdom	BioKinetic Europe Ltd	Belfast	Antrim
United Kingdom	Diabetes Centre, Heartlands Hospital	Birmingham
United Kingdom	NHS Lothian	Edinburgh
United Kingdom	Highland Diabetes Institute	Inverness

Sponsors (2)

Lead Sponsor	Collaborator
LifeScan	Bio-Kinetic Europe, Ltd.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in patient satisfaction ( DTSQ survey)		Baseline and 24 weeks	No
Other	Number of SMS messages sent by the HCP		24 weeks	No
Other	Healthcare efficiency survey by the HCP		12 and 24 weeks	No
Primary	A1c change from baseline in subjects using the OneTouch Verio® Flex BGM and the OneTouch Reveal® Mobile APP system compared to subjects using only the OneTouch Verio® Flex (without Bluetooth) for 24 weeks.		24 Weeks	No
Secondary	A1c = 7.0%		12 and 24 weeks	No
Secondary	Change in A1c from baseline		12 and 24 weeks	No
Secondary	Quantity and percentage of glucose results within personalized glycemic ranges set by HCP at baseline.		12 and 24 weeks	No
Secondary	Percentage of patients that performed SMBG tests as instructed by HCP.		24 weeks	No
Secondary	OneTouch Reveal Mobile APP interaction and usage via APP analytics over 24wks.		24 weeks	No